Opko Health Inc. (OPK) Shares Bought by Legal & General Group Plc
Legal & General Group Plc grew its holdings in shares of Opko Health Inc. (NASDAQ:OPK) by 17.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 141,535 shares of the biotechnology company’s stock after buying an additional 21,017 shares during the quarter. Legal & General Group Plc’s holdings in Opko Health were worth $971,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Blair William & Co. IL bought a new stake in Opko Health during the 2nd quarter worth about $112,000. Engineers Gate Manager LP bought a new stake in Opko Health during the 2nd quarter worth about $117,000. Crossmark Global Holdings Inc. bought a new stake in Opko Health during the 3rd quarter worth about $118,000. Abbot Financial Management Inc. bought a new stake in Opko Health during the 2nd quarter worth about $129,000. Finally, BB&T Securities LLC lifted its position in Opko Health by 7.6% during the 2nd quarter. BB&T Securities LLC now owns 20,600 shares of the biotechnology company’s stock worth $135,000 after buying an additional 1,460 shares in the last quarter. 22.90% of the stock is currently owned by hedge funds and other institutional investors.
In related news, major shareholder Opko Health, Inc. purchased 655,738 shares of the stock in a transaction on Monday, October 30th. The shares were purchased at an average cost of $3.05 per share, with a total value of $2,000,000.90. Following the acquisition, the insider now directly owns 6,678,752 shares in the company, valued at $20,370,193.60. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 40.19% of the stock is owned by corporate insiders.
Shares of Opko Health Inc. (NASDAQ:OPK) opened at $4.97 on Wednesday. The stock has a market cap of $2,780.00, a PE ratio of -26.16 and a beta of 1.81. The company has a quick ratio of 1.48, a current ratio of 1.66 and a debt-to-equity ratio of 0.01. Opko Health Inc. has a fifty-two week low of $4.50 and a fifty-two week high of $9.55.
Opko Health (NASDAQ:OPK) last released its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.03). The company had revenue of $263.50 million during the quarter, compared to the consensus estimate of $319.43 million. Opko Health had a negative net margin of 9.45% and a negative return on equity of 5.17%. The firm’s revenue was down 11.6% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.03) earnings per share. analysts predict that Opko Health Inc. will post -0.27 earnings per share for the current year.
Opko Health Profile
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
Want to see what other hedge funds are holding OPK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Opko Health Inc. (NASDAQ:OPK).
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.